The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InIn a move reflecting the intensifying legal battles over vaccine technology ownership, Arbutus Biopharma and its partner Genevant filed three international lawsuits against Pfizer and BioNTech. The lawsuits allege that the companies infringed on patents related to lipid nanoparticle (LNP) technology used in COVID-19 vaccines. Concurrently, Arbutus confirmed receiving the first payment from a separate settlement agreement with Moderna and announced plans to return capital to shareholders.
This legal escalation comes as major pharmaceutical firms face mounting pressure regarding intellectual property rights, following the massive revenues Pfizer generated from its vaccines in recent years. Per market data, peer performance remains mixed as investors weigh the potential impact of these legal overhangs on future cash flows. Experts suggest that such patent disputes are becoming a standard risk factor in the post-pandemic biotech landscape.
Regarding market levels, PFE stood at $24.82, while BNTX closed at $91.99 and MRNA at $68.28 (at close July 15, 2026). Investors are now monitoring for further judicial developments that could trigger additional settlements, alongside the upcoming U.S. Monetary Policy Report later in July, which may influence broader market sentiment toward the healthcare sector.